Is Wegovy Better Than Other Weight-Loss Treatments?

What 'better' actually means in this context

A question our prescribers hear most weeks is some version of this: 'I've seen both Wegovy and Mounjaro mentioned — which one works better?' The honest answer is that 'better' splits into at least three separate questions: better average weight loss in trials, better suited to a particular health profile, and better in practice for someone who, say, finds injections daunting or travels a lot.

On raw trial results, Wegovy at 2.4mg produced roughly 15% average body-weight reduction at 68 weeks in STEP 1, published in the New England Journal of Medicine. That was transformative compared to what weight-loss pharmacotherapy had previously achieved. The newer 7.2mg dose pushes closer to 21% average loss, narrowing the gap with tirzepatide considerably. Both figures come from controlled trials with lifestyle support alongside the medicine, results in practice vary.

What Wegovy also has that most alternatives lack is a cardiovascular outcome trial showing it reduces the risk of major cardiovascular events in eligible adults with obesity. For someone whose GP has flagged heart risk alongside their weight, that additional licence matters clinically. The decision isn't simply about which number is bigger.

How Wegovy compares to tirzepatide, the main alternative

The SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, ran tirzepatide directly against semaglutide 2.4mg in 751 adults with obesity and without type 2 diabetes over 72 weeks. Tirzepatide (the active ingredient in Mounjaro) produced greater average weight reduction. NICE's appraisal of tirzepatide, TA1026, references this and notes that indirect comparisons also favour tirzepatide at higher doses.

That said, 'greater average loss' in a population-level trial doesn't translate cleanly to any individual. Some people tolerate one medicine's side-effect profile better than the other's. Both are GLP-1-based, so nausea, constipation, and slowed digestion feature in both; tirzepatide adds GIP receptor activity, which may alter how some people respond. Our semaglutide overview and the Wegovy treatment page set out the mechanisms side by side if you want the detail.

Cost is part of the picture too. Prices vary by dose and provider; Wegovy's cost in the UK has shifted since Eli Lilly's list-price change in September 2025 moved the overall market. For a prescription medicine, the cheaper option isn't necessarily the right one, what the price includes (clinical oversight, aftercare, genuine supply chain) matters as much as the headline figure.

Where Wegovy stands on its own terms

Wegovy has a well-established UK safety record and a broad evidence base built across the STEP programme trials. It's licensed for adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. Lower thresholds apply for some ethnic backgrounds under UK guidance. The 7.2mg pen, approved in April 2026, is specifically for adults with a BMI of 30 or above, the cardiovascular indication has its own eligibility criteria assessed separately.

For people who prefer not to inject, Novo Nordisk's oral semaglutide tablet (Wegovy tablets) received MHRA approval in June 2026 as the first oral GLP-1 licensed for weight management in the UK, trial data showed around 13.6% average weight loss over 64 weeks. That's a genuinely different option within the semaglutide family, and one where how you take it has real bearing on how well it works.

Side effects are worth a realistic look before you start. GI symptoms (nausea, loose stools, reflux, occasional vomiting) are the most commonly reported across both semaglutide and tirzepatide. They tend to be front-loaded, peaking in the weeks after starting or after a dose step, then easing. Timing your dose can help; some people find taking Wegovy in the evening reduces how much nausea affects their day. Managing the first weeks is something our aftercare team supports actively. If you have concerns about specific side effects, the NHS semaglutide medicine page lists them clearly.

Making the call: a clinical decision, not a ranking

Wegovy is better than older weight-loss medicines by most evidence-based measures. Against tirzepatide, the comparison is more evenly matched at the highest doses, with tirzepatide currently holding a trial-data edge on average weight loss. Neither medicine is universally 'best', the right fit depends on your BMI, health history, how you respond to the starting doses, and whether cardiovascular benefit or the oral option changes the equation for you.

If you're exploring your options, the weight-loss treatment overview covers what's currently licensed in the UK and how the medicines differ at a practical level. When you're ready to talk to a prescriber rather than read further, starting a free consultation is the point at which the comparison becomes a personal recommendation.